Rapid Spread of JN.1 Variant Raises Concerns

The World Health Organization has declared the JN.1 subvariant of the coronavirus a variant of interest due to its rapid spread, accounting for 27.1% of global cases in November. While JN.1 has an additional spike protein mutation compared to its parent variant, the WHO does not expect it to pose a significant public health risk. Symptoms of JN.1 are not known to differ significantly from other variants, and existing COVID-19 tests, treatments, and vaccines are expected to be effective against it. JN.1 has been detected in 41 countries, with the highest proportion of cases in France, the United States, Singapore, Canada, the United Kingdom, and Sweden.